Scleroderma Research Foundation (EIN 680087234) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

1987

Legal Domicile

Principal Officer

Joanne Gold

Phone

4158349444

Tax Period

2024-01-01 to 2024-12-31

Scleroderma Research Foundation, founded in 1987, is a mid-sized nonprofit in the Medical Research sector that reported $12.2M in total revenue in fiscal year 2024. Revenue surged 45% from the prior year, signaling strong growth momentum. The organization ran a surplus of $2.6M, a strong 21% operating margin.

Mission

The SRF is laser-focused on finding a cure for scleroderma by raising critical funds for research investments, fostering collaboration among the worlds top scientists and institutions to drive innovation, and raising awareness about this rare disease.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $4,457,144

Program Service Revenue $6,657,855

Investment Income $1,211,667

Other Revenue $-153,505

TOTAL REVENUE $12,173,161

Expense Breakdown

Grants Paid $3,392,838

Salaries & Benefits $1,606,446

Fundraising Expenses $690,399

Program Expenses $8,542,859

Other Expenses $4,623,237

TOTAL EXPENSES $9,622,521

Year-over-Year Comparison

	2024	2023	Change
Revenue	$12,173,161	$8,418,038	+0.4%
Expenses	$9,622,521	$6,487,599	+0.5%
Net Income	$2,550,640	$1,930,439	+0.3%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

255

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$229,836

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
Gregory Gordon	Chief Medical Officer	40.00		$416,000	$935	$416,935
Joanne Gold	Executive Dir.	40.00	Officer	$215,900	$13,936	$229,836
Gloria Blecha	VP Communications	40.00		$171,600	$16,022	$187,622
Kate Ceredona	Dir. Philanthropy	40.00		$152,258	$7,819	$160,077
Hannah Young	Dir. Communication	40.00		$130,007	$7,120	$137,127
Luke Evnin PhD	Chairman	30.00	Officer Director	$0	$0	$0
Susan Feniger	Secretary	10.00	Officer Director	$0	$0	$0
Deann Wright	Treasurer	10.00	Officer Director	$0	$0	$0
Omar Baker MD	Board Member	2.00	Director	$0	$0	$0
Sharon Dobie MD	Board Member	2.00	Director	$0	$0	$0
Eric Kau MD	Board Member	2.00	Director	$0	$0	$0
David Knoller	Board Member	1.00	Director	$0	$0	$0
Violetta Merin	Board Member	2.00	Director	$0	$0	$0
Regina Hall	Board Member	2.00	Director	$0	$0	$0
Jeff Seaman	Board Member	2.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	$12,173,161	$9,622,521	$32,999,784	$2,550,640
2023	$8,418,038	$6,487,599	$18,654,748	$1,930,439
2022	$5,892,738	$4,658,602	$11,143,637	$1,234,136
2021	$3,768,969	$3,687,303	$9,819,469	$81,666
2020	$3,931,140	$2,957,771	$9,592,172	$973,369
2019	$5,168,122	$3,364,239	$7,445,548	$1,803,883
2018	$4,733,081	$3,005,455	$5,318,800	$1,727,626

Scleroderma Research Foundation